Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 216,037
  • Shares Outstanding, K 198,199
  • Annual Sales, $ 332,310 K
  • Annual Income, $ -51,750 K
  • EBIT $ -40 M
  • EBITDA $ -38 M
  • 60-Month Beta 0.67
  • Price/Sales 0.70
  • Price/Cash Flow 48.70
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 154.23% ( +32.68%)
  • Historical Volatility 91.43%
  • IV Percentile 82%
  • IV Rank 16.45%
  • IV High 719.03% on 04/09/25
  • IV Low 42.99% on 10/23/24
  • Put/Call Vol Ratio 0.24
  • Today's Volume 519
  • Volume Avg (30-Day) 1,741
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 75,077
  • Open Int (30-Day) 65,441

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.17
  • Number of Estimates 5
  • High Estimate -0.13
  • Low Estimate -0.19
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -240.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7600 +43.42%
on 05/23/25
1.2700 -14.17%
on 06/06/25
+0.2882 (+35.94%)
since 05/16/25
3-Month
0.6925 +57.40%
on 05/15/25
1.7500 -37.71%
on 03/24/25
-0.4500 (-29.22%)
since 03/17/25
52-Week
0.6925 +57.40%
on 05/15/25
3.9400 -72.34%
on 12/09/24
-1.7800 (-62.02%)
since 06/17/24

Most Recent Stories

More News
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

ESPR : 1.0900 (-6.84%)
Esperion to Participate in Upcoming June Investor Conferences

ESPR : 1.0900 (-6.84%)
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

ESPR : 1.0900 (-6.84%)
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

ESPR : 1.0900 (-6.84%)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPR : 1.0900 (-6.84%)
HLS Therapeutics Announces Q1 2025 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

ESPR : 1.0900 (-6.84%)
HLS.TO : 4.97 (-0.40%)
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada

– These cardiovascular medicines have the potential to address a significant unmet medical need for over half a million Canadians – HLS will leverage existing...

ESPR : 1.0900 (-6.84%)
HLS.TO : 4.97 (-0.40%)
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

ESPR : 1.0900 (-6.84%)
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion Therapeutics ESPR incurred a loss of 21 cents per share in the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, Esperion...

ESPR : 1.0900 (-6.84%)
IMCR : 32.36 (-1.67%)
ANIP : 63.35 (-1.46%)
NTLA : 9.58 (+6.92%)
Esperion Therapeutics: Q1 Earnings Snapshot

Esperion Therapeutics: Q1 Earnings Snapshot

ESPR : 1.0900 (-6.84%)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 1.2367
2nd Resistance Point 1.2033
1st Resistance Point 1.1467
Last Price 1.0900
1st Support Level 1.0567
2nd Support Level 1.0233
3rd Support Level 0.9667

See More

52-Week High 3.9400
Fibonacci 61.8% 2.6995
Fibonacci 50% 2.3163
Fibonacci 38.2% 1.9330
Last Price 1.0900
52-Week Low 0.6925

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar